Mirzaten (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine and serotonin. It also antagonises postsynaptic 5‑HT2, 5‑HT3 and histamine H1 receptors, providing antidepressant, anxiolytic and sedative effects.

The appropriate dose of Mirzaten is determined by the prescribing clinician based on the individual’s clinical condition, response to therapy and tolerability. Dosage adjustments may be made during treatment, and patients should follow the prescriber’s instructions exactly.

Safety data for mirtazapine in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and discuss the decision with the patient. Women who are pregnant, planning pregnancy, or breastfeeding should consult their physician before using Mirzaten.

To order Mirzaten, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Unlike selective serotonin reuptake inhibitors (SSRIs), mirtazapine primarily enhances norepinephrine and serotonin release by blocking α2‑adrenergic receptors and also has strong antihistamine activity, which can cause sedation and weight gain. This profile makes it useful for patients with depression accompanied by insomnia or loss of appetite, whereas SSRIs are generally more activating and have a different side‑effect spectrum.

Mirzaten tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Mirzaten is taken orally, usually once daily in the evening with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include the development of agranulocytosis or severe neutropenia, severe skin reactions such as Stevens‑Johnson syndrome, worsening depression or emergence of suicidal thoughts, and rare cases of hepatotoxicity. Patients should seek immediate medical attention if they notice signs of infection, rash, or a sudden change in mood.

Mirzaten is contraindicated in patients who have taken monoamine oxidase inhibitors (MAOIs) within the past 14 days, those with known hypersensitivity to mirtazapine, and individuals with severe hepatic impairment where dose adjustment is not feasible. Caution is also advised for patients with a history of bipolar disorder, as antidepressants can precipitate mania.